arrow
W

Wai Chin Foo

The University of Texas MD Anderson Cancer Center
H指数:25
被引数:4,136

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

对伊匹木单抗和纳武利尤单抗在转移性去势抵抗性前列腺癌中的应答和耐药免疫生物标志物

2026-01-010
OA
ASO Visual Abstract: Clinicopathologic and Molecular Characteristics of High-Grade Appendiceal Mucinous Neoplasms

ASO视觉摘要:高级别阑尾黏液性肿瘤的临床病理及分子特征

2025-12-090
PRE
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer

Ⅰ/Ⅱ期临床试验:encorafenib、cetuximab和nivolumab在微卫星稳定型BRAFV600E转移性结直肠癌中的应用

2025-08-280
OAAI
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
2024-08-270
OAAI
Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort
2024-04-050
PRE
Serum Tumor Markers and Outcomes in Patients With Appendiceal Adenocarcinoma
2024-02-285
OAAI
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial

全身化疗对低级别黏液性阑尾腺癌患者的疗效: 一项随机交叉试验

2023-06-019
OAAI
Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases
2021-04-0233
OA
Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer

阑尾腺癌的综合临床分子谱分析揭示了与结直肠癌不同的独特等级驱动实体

2020-07-3121
OAAI